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ABSTRACT 
 
In spite of the current advances in both radiotherapy and surgical techniques as well as 
molecularly targeted therapies, over 90 percent of cancer mortality rate is due to metastases. 
Considering the pivotal role of metabolism in cellular physiology, there is no doubt that metabolic 
alterations are critical for metastatic progression.  
 
Cardiolipin (CL), the signature phospholipid of mitochondria, is linked to a variety of vital 
mitochondrial processes, like oxidative phosphorylation. Cardiolipin is a unique dimeric 
phospholipid which contains four fatty acyl chains. Moreover, the CL remodeling process is 
believed to be responsible for generation of immature CL species that contribute to tumor growth 
progression. Abnormalities in CL composition and/or content have been discovered in various 
solid tumors. Cancer cells prefer saturated fatty acids over polyunsaturated fatty acids to avoid 
apoptosis triggered by CL peroxidation in mitochondria. However, little is known about the 
biochemical basis of the action of CL remodeling on breast cancer cell proliferation and metastasis. 
The effects of two potent phospholipase inhibitors which are bromoenol lactone [BEL], a calcium-
independent phospholipase A2 inhibitor, and halopemide, a phospholipase D inhibitor, were 
examined on MDA-MB-231, MCF-7 cell lines and their corresponding bone metastasis BoM and 
MCF-7/BoM cell lines to study the role of CL remodeling on the progression of breast cancer and 
CL extraction method from breast cancer metastatic cells were established.
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CHAPTER I: INTRODUCTION: 
1.1. Breast Cancer 
Other than skin cancer, breast cancer is the most common form of solid tumor in women 
with increasing mortality rate in America, Europe, Asia, and Africa.1 According to the National 
Cancer Institute, there will be 268,600 new cases of and the disease, among which 41,760 women 
will die in 2019.2 
 
These malignant tumors display discrete immunohistochemical profiles that are created by 
cancer cells within specific microenvironments, with unique intercellular cross talk which is linked 
to various clinical outcomes.3 Specifically, based on evidence from malignant breast tumor 
immunohistochemistry, breast cancer is divided into three major types, that include estrogen (ER+) 
and progesterone (PR+) receptor—positive, human epidermal growth factor receptor 2 
overexpressing (HER2+), and ER-, PR-, HER2- or triple-negative breast cancers (TNBCs). 
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Figure 1. Breast cancer classification of into three major types according to their 
immunohistochemical properties, in addition to their relative prognosis (adapted from Cells 2019, 
8, (401). 1-30).1  
 
The previously described breast cancers have different prognoses (Figure 1). Estrogen 
(ER+) and progesterone (PR+) receptor–positive breast cancer is divided into two subtypes: luminal 
A including ER+ and/or PR+ and HER2- breast cancer which is distinguished by low Ki-67 
proliferation marker expression; and luminal B, which is ER+ and/or PR+, HER2+ (or HER2-) 
breast cancer that highly expresses Ki-67 and is associated with poor prognosis relative to luminal 
A-forms. The HER2+ expressing breast cancers are considered aggressive or malignant tumors that 
are associated with increased mortality and recurrence rate, in increased risk of metastasis 
progression. However, TNBCs account for about 12% of all breast cancers are the most 
heterogeneous subtype of breast cancer with the highest risk of recurrence and the shortest overall 
survival rates.3,4 
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One of the significant characteristics of solid tumors is abnormal extrinsic 
microenvironments, including alterations in the extracellular matrix (ECM), blood and lymphatic 
tumor vessels, and non-cancerous stromal cells. These stromal cells are characterized by 
endothelial cells, immune cells, pericytes, activated adipocytes, cancer-associated fibroblasts 
(CAFs), and mesenchymal stem cells (MSCs), as well as epithelial cancer cells 5. As a result of 
interaction between tumor cells and their microenvironment components which act as metabolic 
ecosystems, proliferating tumor cells employ unique molecular mechanisms that range from 
intrinsic genetic mutations to extrinsic micro-environmental factor(s)-activated signaling 
pathways to modify their cellular metabolism.6-8  
 
Metabolic plasticity is considered as a distinct hallmark of breast cancer cells. Notably, the 
primary source of energy in many breast cancer cells is aerobic glycolysis, called the Warburg 
Effect.8,9 This effect represents a metabolic phenotype of tumor cells that is associated with a 
metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis for ATP production, even 
in the presence of relatively high oxygen tension, to simultaneously provide crucial building blocks 
required for rapid proliferation and growth.1 By contrast, experimental evidence also indicates that 
OXPHOS plays an important role in tumor growth and progression. Moreover, emerging evidence 
has demonstrated that cancer metabolism is not a static process, as tumor metabolism can be altered 
to compensate for cellular needs. The cellular requirements are monitored by the interactions 
between tumor and its microenvironmental crosstalk which produces a hybrid 
glycolysis/OXPHOS phenotype. This phenotype accelerates the metabolic plasticity of tumor 
cells, and is believed to contribute to metastasis and therapeutic-resistance.10  
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1.2. Breast Cancer Metastasis 
In spite of current advances in radiotherapy, surgical techniques, and molecular-targeted 
therapies, over 90% of cancer mortality remains to be associated with secondary metastatic 
tumors. Secondary metastatic cancers are caused, in part, by progressive promotion of 
therapeutically resistant metastases that arise following primary therapies.11,12 These tumors 
develop resistance either by activating complimentary signaling pathways or by acquiring new 
mutations. Therefore, there is no current treatment option which can efficiently and selectively 
curb the spread of many tumor cells to vital organs.12-14 
 
Research and clinical results have confirmed Paget’s century-old “seed and soil” 
hypothesis. This details that favorable interactions between metastatic tumor cells, the “seed,” and 
their organ-unique microenvironment, the “soil,” that generates a preferential pattern of organ-
specific tumor metastasis (also known as “organotropism”). The invasion and intravasation of 
metastasis-initiating tumor cells into the vasculature, surviving circulation, and extravasation into 
distant target organs, form micro-metastases, and progress from a state of dormancy to outgrow 
into secondary lesions.11,13 While enormous number of tumor cells are released into circulation, 
only about 0.01% succeed in creating metastases. In breast cancer, secondary lesions are often 
formed in the lungs, bones, brain, and liver.12-14 The site-specific metastases vary in terms of 
evolution, growth rate, hormone receptors, immunogenicity, sensitivity to cytotoxic drugs, 
morbidity, and mortality. The interactions between tumor microenvironment and genetic mutation 
influence both organ tropism and metastatic propensity.15 Research has led to breakthroughs in 
regard to identifying the target organ-dependent gene expression profile signatures that are 
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predictive of breast cancer bone-, brain-, and lung-specific metastases.15-17 However, the 
connections between tumor metastasis and metabolism are less defined. Currently, metabolomic 
profiles indicate that the acquisition of a glycolytic phenotype is associated with rising metastatic 
potential.8 Considering the pivotal role of metabolism in cellular physiology, there is no doubt that 
metabolic alterations are critical for metastatic progression. Targeting metastasis-specific tumor 
metabolism represents a potentially straightforward means to more effectively curb metastasis. 
 
Figure 2. Tumor progression, growth and metastatic dissemination steps. The scheme illustrates 
different pathologically identified tumor progression stages; and various functions associated with 
metastatic spread. The functions linked to dissemination may be general metastasis mediators. In 
the purple box, subsequent functions are required for metastatic colonization which could be 
distinct to the micro-environmental factors of the various metastatic sites (adapted from Cold 
Spring Harb Symp Quant Biol 2005, 70, 149-58).15  
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1.3. Mitochondria: Physiology and the Role of their Membrane Lipids 
Mitochondria which act as energy-producing organelles are membrane-enclosed cellular 
structures, and their influence extends to a number of other cellular functions.18 Mitochondria have 
a unique structure that includes two membranes. The first membrane is a smooth outer 
mitochondrial membrane (OMM) and the second is an inner mitochondrial membrane (IMM), 
composed of many invaginations called cristae.18,19 The bioenergetics of mitochondria primarily 
depends on the inner mitochondrial membrane (IMM) physiology that hosts the respiratory system 
and phosphorylation redox complexes. The complexes that carry out the oxidative phosphorylation 
are considered to function as a highly efficient concerted energy-generating process. In this 
process, the energy produced from nutrient oxidation is used to drive ATP generation.18 Further, 
mitochondrial oxidative phosphorylation is responsible for approximately 90% of cellular oxygen 
consumption and provide more than 80% of the energy needed for cellular metabolism. Moreover, 
mitochondria have other functions in the cell which include the maintenance of cellular redox 
balance, the housing of important biosynthetic pathways, the modulation of calcium signaling, and 
in the regulation of cell death.18,20 
 
Mitochondria are not static entities and can be extremely dynamic. Mitochondria require a 
source of membrane lipids and a supply of specific proteins to be coordinated and adjusted in order 
to achieve physiological and biochemical demands.21,22 The lipids of the mitochondrial membranes 
are involved in many processes, such as energy production, protein biogenesis, membrane fusion, 
and apoptosis.18-23 Further, spatially defined lipid distribution may also influence mitochondrial 
processes, such as fission, fusion, or the membrane plane protein topology.18 Cardiolipin, the 
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signature phospholipid of mitochondria is the perfect example of the crucial role of membrane 
lipids in mitochondria function. Cardiolipin is linked to a variety of vital mitochondrial processes, 
like oxidative phosphorylation, apoptosis, and to the assembly and functionality of mitochondrial 
membrane proteins. Alterations in the CL pool is associated with many life-threating 
mitochondrial dysfunction-related diseases, such as Barth Syndrome, cancer, diabetes, and other 
metabolic diseases.18,24   
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1.4. Cardiolipin Metabolism  
1.4.1. Cardiolipin Structure  
Cardiolipins are a unique class of anionic phospholipids, and which predominantly, or 
nearly exclusively, are found in mitochondrial membranes, and are mainly localized in the 
mitochondrial inner membrane.18,24 Each CL molecular species (1,3-diphosphatidyl-sn-glycerol) 
is composed of a dimer of two phosphatidyl moieties, three distinct glycerol moieties with three 
stereogenic centers, and four fatty acyl chains.25,26 
  
Figure 3. The unique conical structure of cardiolipin promotes curvature in lipid membranes. (A) 
Phosphatidylcholine chemical structure (PC). (B) Cardiolipin (CL). chemical structure (C) 
Cardiolipin exerts lateral pressure in a lipid bilayer to induce a negative curvature (adapted from 
Cell Mol Life Sci 2008, 65, (16), 2493-506.).24 
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1.4.2. Cardiolipin Biosynthesis and Remodeling 
The synthesis of the vast majority of mitochondrial membrane lipids occurs in the 
endoplasmic reticulum. Contrary to this, de novo CL biosynthesis exclusively takes place in the 
mitochondrial inner membrane (Figure. 3).24,27-31 The mitochondrial CDP-DAG synthase, an 
enzyme that catalyzes the first reaction of CL biosynthesis, converts mitochondrial phosphatidic 
acid (PA) to CDP-diacylglycerol (CDP-DAG). Phosphatidylglycerophosphate synthase 1 (Pgs1) 
transfers the CDP-DAG phosphatidyl group to glycerol-3-phosphate to generate 
phosphatidylglycerolphosphate (PGP). The PGP phosphatase catalyzes the subsequent PGP 
dephosphorylation to phosphatidylglycerol (PG). The final reaction of de novo CL synthesis is 
catalyzed by CL synthase (Crd1) which is responsible for adding a phosphatidyl group from CDP-
DAG to PG. The result produces CLs that contain two phosphatidyl groups that are connected by 
a glycerol molecule.24,27-31 
 
The cardiolipin remodeling processes is characterized by the removal and replacement one 
acyl chains with other acyl chains.29,31 Cardiolipin remodeling plays a vital role in creating 
symmetrical CL with characteristic fatty acid residues following de novo synthesis because the 
enzymes involved in de novo CL synthesis do not exhibit acyl chain-substitution specificity. There 
are two mechanisms by which CL remodeling can occur. In the two-step mechanism, CL is 
remodeled through the deacylation-reacylation cycle in which phospholipid is deacylated by 
phospholipases to form lysophospholipid. Then, acyltransferases or transacylases catalyze the 
addition of acyl groups that derive from acyl-CoA or neighboring phospholipids to the 
lysophospholipid. In this process, phospholipases deacylate CL and monolyso-CL (MLCL) are 
reacylated to CL by either acyltransferase or transacylase. However, in one-step CL remodeling 
10 
 
 
reaction, acyl groups are exchanged between adjacent phospholipids in a single transacylase-
catalyzed step.  During this single step, tafazzin, the transacylase remodeling CL, catalyzes CL 
remodels through only transacylation, in which the deacylation of phospholipids is not 
required.29,31 
 
Figure 4.  Model of CL biosynthesis and remodeling in pediatric heart failure: Acyl-CoA, acyl-
coenzyme A; CL, cardiolipin; CDP-DAG, cytidinediphosphate-diacylglycerol; CDS, CDP-DAG 
synthase; CLS, CL synthase; CMP, cytidinemonophosphate; CoA-SH, coenzyme A 
(unconjugated); CTP, cytidinetriphosphate; DLCL, Dilyso-CL; FFA, free fatty acid; G3P, 
glycerol-3-phosphate; MLCL, monolyso-CL; MLCL-AT, MLCL acyltransferase; PG, 
phosphatidylglycerol; PGP, PG phosphate; PGPS, PG-P synthase; PGPP, PG-P phosphatase; Pi, 
inorganic phosphate; PLA2, phospholipase A2; TAZ, tafazzin (adapted from Am J Physiol Cell 
Physiol 2007, 292, (1), C33-44.).31 
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1.5. Mitochondrial Cardiolipin and signaling during Apoptosis  
Apoptosis is a controlled process of cell death to maintains the homeostasis of cell 
populations in tissues; and occurs as a defense mechanism in damaged cells or in immune 
reactions.28 There are a number of reports indicating that during apoptosis, many alterations in 
mitochondrial lipid content and distribution occur. Among these alternations, in mouse liver 
mitochondria, an increase in monolysocardiolipin (MLCL).18 
 
Cardiolipin is highly vulnerable to oxidative damage not just for its high content of 
unsaturated fatty acids, but also for its location which is near the site of ROS.24,30,32. Mitochondrial 
H2O2 can oxidize cardiolipin; however, in the presence of cyt c, this oxidation is significantly 
enhanced.33 The dramatic enhancement of the protein’s peroxidase activity is due to the interaction 
of cyt c with cardiolipin which promotes cyt c unfolding. The native cyt c is a compact tertiary 
structure with a coordination of its heme iron to Met80 and His18. This is reported that native cyt 
c shows very low peroxidase activity which results from its hexacoordinated iron. There exists 
substantial unfolding of cyt c according to the reports which have examined cyt c and cardiolipin 
liposomes. The unfolding of cyt c can disrupt the Met80 ligation and exposes the heme iron to 
H2O2. There are other researchers who report deep penetration of one or two acyl chains of 
cardiolipin into the hydrophobic core of cyt c. This can also lose the Met80-Fe axial bond. The 
cardiolipin oxidation produces kinks in the acyl chain.24 This oxidation disturbs cardiolipin 
microdomains on the IMM and also causes curvature loss (Figure 5). In addition, cyt c is detached 
from the IMM due to the disruption of super complexes. All in all, this mitochondrial respiration 
inhibits which sets the stage for apoptosis. There is a synergy between oxidized cardiolipin and 
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Ca2+ which make the mitochondrial permeability transition (MPT) pore open. It is believed that 
the identity of the MPT pore is remains elusive, but non-specific which allows any molecules <1.5 
kDa have free passage. There are several parts, including the voltage-dependent anion channel, the 
adenine nucleotide translocator and the F0F1-ATP. The permeability barrier of the IMM is 
disrupted by mitochondrial permeability transition. Therefore, there is a collapse of the 
mitochondrial potential and uncoupling of oxidative Additionally, cyt c and other proapoptotic 
proteins are released into the cytosol as a result if which the caspase cascade and cell death are 
triggered by apoptosis. Necrosis can make cell death die due to severe depletion of ATP This is 
interesting to note that in IMM-OMM contact sites, CL and phosphatidylethanolamine (PE) are 
predominate.18,24 The two phospholipids are non-bilayer lipids. These characteristics help them to 
adopt an inverted hexagonal phase (HII) when there are no membrane constraints. Although the 
lipids are to some extent speculative, at the contact sites, it is assumed that, non-bilayer lipids could 
be involved in membrane fusion. The involvement fosters CL access to the cytosolic face of OMM. 
where it would have direct interaction with t-Bid. This offers docking site for this active form of 
the pro-apoptotic protein Bid which is considered as the first step in triggering the action of Bax 
and Bak (other pro-apoptotic Bcl-2 proteins). This leads to OMM permeabilization. According to 
more recent reports, there is an involvement of CL-enriched contact sites in apoptosis-associated 
events. In the current research study, there is a hypothetic model proposing a contact sites act as 
activating platforms (raft like microdomains). Within these platforms, caspase-8 is anchored which 
cleaves its substrate (Bid). The T-Bid is the resulting product which is then recruited to promote 
Bak/Bax oligomerization. Membrane defects would be created due to the segregation of these 
domains from the rest of the OMM which fosters apoptogenic factor leakage.18, 24  
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Figure 5. Cardiolipin microdomains and peroxidation. Cardiolipin microdomains is destabilized 
by cardiolipin peroxidation on the inner mitochondrial membrane (IMM) and disrupts 
supercomplexes. Cardiolipin (CL) is sensitively vulnerable to oxidative damage for the high 
amounts of unsaturated fatty acids. The structure of cardiolipin (CLOOH) is altered by 
peroxidation of the acyl chains. As the result of which cardiolipin is prevented from aggregating 
into microdomains or rafts on the IMM. Cristae curvatures is abolished due to the breakdown of 
cardiolipin rafts which results in the disruption in the organization of respiratory complexes into 
higher order supercomplexes. The affinity for cyt (C) is also reduced by peroxidation of cardiolipin 
which makes the setting ready for the stage for cyt c to release into the cytosol and apoptosis. IMS: 
intermembrane space (adapted from Cell Mol Life Sci 2008, 65, (16), 2493-506.).24 
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1.6. Cardiolipin Remodeling in Tumor Cell Survival 
Metabolic reprograming in cancer involves a process of unique alterations in mitochondrial 
membrane composition. Results from analysis of the inner membrane lipid composition in the 
mitochondria from various tumors indicate an increased cholesterol content and alterations in the 
relative content of various phospholipids species.18 In addition, changes in lipid acyl chain 
components are also observed. In general, the mitochondria phospholipids coming from tumor 
cells are shorter and have fewer unsaturated acyl chains compared with those from normal cells. 
These alterations of the lipid composition in mitochondrial membranes are believed to impact the 
mitochondrial phenotype which contributes to the Warburg Effect, and a decreased susceptibility 
to apoptotic stimuli. Dynamic processes in the altered mitochondrial membrane composition of 
cancer cells may be responsible for the susceptibility reduction in the respiratory chain activity; a 
relationship that has already been established for CL. On the other hand, remodeling of the 
mitochondrial membrane lipid composition can also lead to rise in mitochondrial membrane 
potential (∆Ψ) which is observed in some cancer cells.18,34  
 
Recently, CL has captivated considerable interest in cancer research. For example, a 
shotgun lipidomics study focused on determining CL in mitochondria from subcutaneous brain 
tumors, a stem cell tumor, an astrocytoma, an ependymoblastoma, and two microgliomas provided 
evidence that indicates that there is an alteration in CL content and composition in tumors.34 
Deformities in CL biosynthesis and remodeling processes may cause abnormalities which include 
an abundance of immature molecular species along with the alteration of mature fully formed CL 
species. Overall, in terms of cancer, the data regarding these mitochondrial phospholipid, is 
15 
 
 
somewhat divergent; ranging from the CL content reduction in brain tumors and the appearance 
of immature molecular species.18,34 as well as a CL content reduction in rhabdomyosarcoma cells.33 
In a peritoneal carcinoma rat model an increase in CL content and CL-fatty acid remodeling was 
observed, while no change in total CL was measured in a separate mouse strain with high 
propensity to form spontaneous gliomas.34,35 
 
In regard to chemotherapeutic-resistance phenotype, various studies on MCF-7 human 
breast cancer cells have explained an increase in CL content (expressed in the percentage of cell 
total phospholipids) in doxorubicin- and cisplatin-resistant cancer cells compared to drug-sensitive 
parental cells.36  
 
Oxidative stress has been connected to tumor initiation and progression. Production of 
reactive oxygen species (ROS) including hydrogen peroxide and superoxide from the 
mitochondrial electron transport chain (ETC) causes oxidative stress to the tumor cells.37 During 
the rapid proliferation, tumor cells develop sophisticated systems to counterbalance the oxidative 
stress. As mitochondria-associated phospholipids, CLs are the principal targets of ROS attack. In 
the most mammalian tissues, tetralinoleoylcardiolipin (TLCL) is the major CL that contains four 
linoleic acid (LA, 18:2, ω-6) chains. Research findings point out that CL peroxidation was 
involved in apoptosis via the release of proapoptotic factors like the cytochrome c (cyt c) from 
mitochondria into the cytosol. The Huiyong Yin and co-workers used a non-targeted metabolomic 
approach in hepatocellular carcinoma HCC tumor tissues. Lower levels of polyunsaturated fatty 
acids (PUFAs) like LA were observed.37 Other studies demonstrated that PUFAs are capable of 
inducing apoptosis through increasing intracellular products of lipid peroxidation.38,39 Another 
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study had employed a lipidomic approach to systematically profile the lipid signatures in HCC and 
adjacent noncancerous tissues and observed a gradual reduction of TLCL and total CL in tumor 
tissues during HCC progression. Moreover, CL oxidation products gradually decreased in tumor 
tissues. In the same study, a significant restoration of apoptotic sensitivity was observed with the 
treatment of sorafenib (Nexavar) or staurosporine, which are the standard treatment for late stage 
HCC patients, after Huh7, HepG2 and LM3 liver cancer cell lines had been incubated with TLCL 
liposome. Similar finding with in vivo results, greater amounts of oxidized CL were observed in 
the mitochondria of TLCL liposome stimulated apoptotic Huh7 cells. These in vivo and in vitro 
findings provide evidence highlighting the significance of reprogrammed CL metabolism in 
apoptosis in the context of oxidative stress associated tumor progression. Seminal work stated by 
Kagan and co-workers, established that oxidation of CL by the cyt c/CL complex was required to 
trigger intrinsic apoptotic pathway.40,41 Later studies demonstrated that enrichment of CL and CL 
peroxidation caused increased cell apoptosis.37 Cancer cells prefer saturated fatty acids over 
PUFAs, such as LA, to avoid apoptosis triggered by CL peroxidation in mitochondria. Consistent 
with this, the main oxidation products coming from TLCL oxidation, were all decreased in tumor 
tissues. Hence, decreased levels of TLCL and CL allowed tumor cells to evade apoptosis through 
attenuating cardiolipin oxidation. Furthermore, major abnormalities in CL content or/and 
composition were also found in mouse brain tumor, which was associated with dramatic reduction 
in ETC activities.34 The CL content was significantly lower in some brain tumors. The molecular 
species of CL either contains predominantly shorter chain saturated or monounsaturated FAs 
which are indicative of immature CL, or contain predominantly longer chain PUFAs that are 
indicative of mature CL.37 Free radical-induced lipid peroxidation has been associated with many 
human diseases including cancer. Robust ROS generation is a common mechanism for various 
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anticancer drugs to kill cancer cells, such as arsenic trioxide,42 doxorubicin, sorafenib, and N-(4- 
hydroxyphenyl) retinamide (4-HPR, fenretinide). However, only limited reports considered the 
crucial roles played by the lipid peroxidation products produced by ROS. Previous studies 
indicated that some PUFAs, such docosahexaenoic acid (DHA), could sensitize various tumor cells 
such as breast cancer, cervical cancer, and ovarian cancer to ROS-inducing anticancer agents.39 
The cytotoxic effect of combined treatment was because of induction of apoptosis, preceded by 
increased generation of intracellular lipid peroxidation products. Also, a recent in vivo study 
showed that ketogenic diet which is high in LAs, and low in protein and carbohydrates enhanced 
radio-chemotherapy responses in lung cancer xenografts through a mechanism that involved 
increased oxidative stress. Ketogenic diets may enrich mitochondrial CL with LA and help them 
to be more sensitive to cell death stimuli. Consequently, these results demonstrated that high 
PUFAs diet, and arachidonic acid (AA) could serve as a potent adjuvant therapy in the treatment 
of cancers by a mechanism linking apoptotic cell death to mitochondrial lipid peroxidation and 
oxidative stress. Many studies have demonstrated that sorafenib induced apoptosis correlated with 
the levels of TLCL and its oxidation, indicating that incorporation of linoleic acid into cardiolipin 
of tumor cells may sensitize the killing of malignant cells by standard treatment with sorafenib in 
HCC.36    
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1.7. Conclusions  
Due to the severity, prevalence, and overall impact of women’s breast cancer, there is a 
high urgent need for the exploration of innovative and effective therapeutic options. The modern 
and advanced treatment options have been proven themselves to be ineffectiveness in curing 
several metastatic forms of breast cancer. In addition, there is a close contribution between the 
metastases of breast tumors on one hand and the high mortality and morbidity rates on the other 
hand. Due to this high rate, there have been continuous attempts to investigate the cause of this 
metastatic potential. Cardiolipin involves in mitochondrial function, apoptosis and also it has strict 
association with mitochondria membrane proteins. This has made several therapies to function as 
potential agents who may succeed; while, the agents targeting other cellular processes fail.  In 
other words, the membrane-lipid therapies are considered as a potentially useful approach which 
can treat cancer and other common pathologies. The membrane-lipid therapies treatment can be 
either on their own or as adjuvants when they are combined with other chemotherapeutic agents. 
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CHAPTER II: CARDIOLIPIN PROFILE IN METASTATIC BREAST CANCER CELLS 
2.1. Introduction 
In an attempt to investigate the effect of cardiolipin profile on the metastatic potential of 
breast cancer cells, the effects of two differentially targeted phospholipase inhibitors were 
evaluated in two pairs of breast cancer cell lines. Cell viability assays were performed in order to 
examine the effects of each inhibitor on the proliferation/viability of each cell line. The first 
inhibitor which is commonly called ‘bromoenol lactone’ (BEL, E-6-(bromoethylene)-tetrahydro-
3-(1-naphthyl)-2H-pyran-2-one) serves as an inhibitor of calcium independent phospholipase A2 
(iPLA2). It is an irreversible, covalent inhibitor of iPLA. Moreover, it has displayed a 1000-fold 
selectivity for iPLA2 in compare to cPLA2 and sPLA2. Thus, BEL is considered a selective 
inhibitor of this enzyme as well as is commonly used to inhibit iPLA2 in cellular systems. BEL is 
usually existed as a racemate. However, the (R)- and (S)-enantiomers of BEL have distinct enzyme 
inhibitory properties. (S)-BEL inhibited iPLA2β 10-fold more potently than (R)-BEL enantiomer. 
While (R)-BEL inhibited iPLA2γ almost 10-fold more potently than (S)-BEL. The iPLA2 family 
of phospholipases has functions in membrane phospholipid remodeling. The second one was 
halopemide which used as an inhibitor of phospholipase D (PLD). Phospholipase D plays a pivotal 
role in the generation of phosphatidic acid (PA) and choline through the hydrolysis of 
phosphatidylcholine (PC). 
20 
 
 
Furthermore, it functions in altering cell morphology and growth. This production of PA 
and choline is crucial in beginning many lipids signaling pathways mediated by PA and other 
cellular messengers such as DAG22. After performing cell viability/proliferation experiments for 
each breast cancer cell line with the various phospholipase inhibitors, 
 
mitochondria were isolated from the different cell cultures and liquid chromatography-
mass spectrometry was performed in order to analyze their cardiolipin profiles. The cell lines 
selected were MDA-MB-231, BoM, MCF-7, and MCF-7-BoM. MDA-MB-231 is a widely studied 
triple-negative breast cancer (TNBC) cell line. The BoM cell lines are bone metastatic subclones 
derived from the MDA-MB-231 cell line. To the contrary, The MCF-7 possesses various genetic 
abnormalities with high amplification. Similarly, The MCF-7-BoM is a bone metastatic variant of 
the MCF-7 breast cancer cell line.  
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2.2. Materials and Methods 
2.2.1. Cell viability assay 
 
Cell culture was performed for each cell line before the cell viability assay was performed. 
Cells were maintained in RPMI-1640 medium with L-glutamine (Gibco), supplemented with 10% 
(v/v) fetal calf serum (FCS, Hyclone) and 50 units mL-1 penicillin and 50 μg mL-1 streptomycin 
(Sigma) (referred to as 'culture media'), at 37°C in a humidified environment (95% Air and 5% 
CO2). For each passage, the cells were detached with 1 mL Trypsin-EDTA (0.25%, Gibco) per 
100 mm plate following removal of the conditioned media. After 5 min incubation at 37°C, culture 
media (9 mL per 1 mL trypsin) was added to neutralize the trypsin. The cell-containing media 
were transferred to a 15 mL centrifuge tube. The tubes were centrifuged at 600 rpm for 5 minutes 
(Jouan C412) and the supernatant removed. The cell pellet was re-suspended in culture media, the 
cell number counted on a hemocytometer, and the cells diluted to desired density.  For cell 
viability/proliferation assay, cells were seed at the density of 1x106 cells/mL in a volume of 100 
µL per well into 96-well plates and incubated for 24 h before the addition of test compounds. The 
stock solutions were then prepared for the inhibitors. 
 
Because BEL is stable at maximum concentration of 25 mg/L, the stock solution was 
prepared to be 20 mg/L. This concentration along with the inhibitor’s molecular weight (317.18 
g/mole) was used to calculate the molarity as 63 x 104 μM. To simplify the calculations, 60 mM 
was used. This yielded 5 mg dissolved in 262.7 µL of DMSO for the initial stock solution. Then 
prepared 6 mM for the stock solution by dissolving 50 of 60 mM in 450 µL of DMSO. A 1:10 
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dilution was performed in order to provide samples with the desired concentrations (60, 30, 10, 3, 
1, and 0.3 μM) from the stock solution.  
 
Next, the stock solution for halopemide was prepared. Halopemide is stable at a maximum 
concentration of 10 g/L. This concentration along with the MW of halopemide (416.88 g/mole) 
was used to calculate the molarity as 20 M. This yielded 5 mg halopemide dissolved in 599.7 μL 
of DMSO for the initial stock solution. Then prepared 6 mM for the stock solution by dissolving 
150 μL of 20 mM in 350 μl of DMSO. A 1:10 dilution was once more performed to create samples 
with concentrations of (60, 30, 10, 3, 1, and 0.3 μM). It was not more than 60 μM because it 
contained 0.9% DMSO. Malignant cells cannot tolerate 1% DMSO. The working solutions were 
2X of the final concentration.  The working solutions (100 μL) were added to the wells with 100 
μL conditioned media at the time of seeding and incubation for 48 hrs. Additionally, a media 
control was included in the 96-well plate as well as 10 μM cycloheximide (CHX). For fixing the 
cells, 100 μL of media was removed and 100 μL of 20% TCA was added to each well. The cells 
were incubated at 4°C for one hour. Then, the plates were washed with tap water four times. Each 
plate was left to air dry at room temperature. Next, to stain the cells, 80 μL of Sulforhodamine B 
(SRB) (0.4% w/v in 1% acetic acid) was added to the cells at room temperature for 10 minutes. 
After washing with 1% acetic acid three times, 100 μL of 10 mM Tris base solution was added to 
each well. The plates were placed on a shaker to extract the dye and the absorbance at 490-650 nm 
measured on a plate reader. 
 
The percent control that each inhibitor had on the proliferation of each cell line was 
determined using OD490 values (background at 650 nm subtracted) Data were normalized to the 
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media control and % Inhibition of cell viability and proliferation calculated using the formula: % 
Inhibition = 1 – ODcompound/ODmediaData shown are average +/- standard deviation, calculated using 
one-way ANOVA (Prism 8.2.1). 
 
2.2.2. Clonogenic Assay 
 
From each cell line, the cells were trypsinized using 0.25% Trypsin-EDTA solution and 
counted using a hemocytometer. Into a 6-well plate, 300 cells were seeded in each well in 2 mL 
of 10% FCS RPMI with P/S. To make sure that the cells were spread equally, the plates were put 
in plate shaker for 1 min. After an overnight incubation, 1ml from the media was removed and 
1ml of the prepared compound, which were 2X of the final concentration, was added. After 24 
hours, the media was aspirated, the cells washed with X1 DPBS, and then 2 mL of 10% FCS RPMI 
were added with P/S. The media were changed every 2-3 days. After 14 days, the cells were fixed 
using 1 mL of 0.1% crystal violet (0.5 g Crystal Violet (0.05% w/v), 27 mL 37% Formaldehyde 
(1%), 10 mL Methanol (1%), 100 mL 10X PBS (1X), and 863 dH20 to 1 L). Pictures were taken 
and analyzed using Image J software. A cluster with at least 50 cells were considered as a colony. 
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2.2.3. Energy Phenotypes Assay Using Seahorse 
 
Seahorse XF Cell Energy Phenotype Test (Agilent Technologies) was performed according 
to the manufacturer’s protocol for the Seahorse XF-96 instrument. The test measures the utilization 
of each pathway- mitochondrial respiration and glycolysis. First under the starting medium 
conditions (Baseline Phenotype) and then upon injection of a stressor mix that induces an energy 
demand (Stressed Phenotype). The Seahorse XF Cell Energy Phenotype Test Report Generator 
plots these data on the Energy Map and displays the Metabolic Potential of the cells. 
 
Briefly, MDA-MB-231 and MCF-7 cells (ATCC) were maintained in DMEM/High 
Glucose media (Hyclone) supplemented with FCS (10%, w/v) or supplemented with Charcoal 
Stripped Fetal Bovine Serum (Hyclone), and penicillin (50 units mL-1) and streptomycin (50 
µg mL-1). Exponentially grown cells were seeded at the density of 6000 cells/well in a volume of 
80 µL into XFe96-well cell culture plates. An Agilent Seahorse XFp Sensor Cartridge was 
hydrated overnight in sterile ddH2O at 37 °C in a non-CO2 incubator overnight, and switched to 
the Agilent Seahorse XF Calibrant the next day. After an overnight incubation, the cells were 
washed in pre-warmed XF assay media (DMEM basal media supplemented with 1 mM pyruvate, 
2 mM glutamine, and 10 mM glucose, adjusted to pH 7.4). Cells were then maintained in 180 
µL/well of XF assay media at 37 °C for 1 h in the absence of CO2. Oligomycin and FCCP were 
combined in a single tube to create a 10x solution (10 µM each). The stressor mix (20 μL) was 
added into port A of the sensor plate. The program was run at baseline for 3 cycles (3 min mix; 0 
min wait; 3 min measure) and control/experimental for 3 cycles (3 min mix; 0 min wait; 3 min 
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measure). Data sets were analyzed using Seahorse XF Cell Energy Phenotype report generator and 
GraphPad Prism software. 
 
2.2.4. Cardiolipin Extraction 
 
A cardiolipin extraction was performed from whole-cell using 20 x106 cells and 60x106 
cells/ cell lines. The cell pellet was first suspended in a disposable borosilicate glass tube (16 × 
100 mm) with 1.00 mL deionized water. Then, it was sonicated for 10 s (2 s/cycle × 5 cycles) on 
ice using a tip sonicator to produce cell homogenate. Cell homogenates were transferred into a 
disposable borosilicate glass tube (13 × 100 mm). 
 
Next, 10.0 µL of working solution (77.8 nM) of tetramyristyl-CL (1,1',2,2'-
tetratetradecanoyl cardiolipin, Avanti Polar Lipids), internal standard (IS) solution was added; 1.50 
mL of chloroform/methanol (1:1, v/v) was added. Then, the mixture was vigorously shaken for 2 
min and placed in ice for 15 minutes, followed by centrifugation at 10 °C and 2000 × g for 5 
minutes. The lower organic layer was transferred to a borosilicate glass tube (13 × 100 mm); while, 
the remaining protein disk and the upper aqueous layer were extracted again with 1.50 mL 
chloroform/methanol (2:1, v/v). Two organic layers were combined and centrifuged at 10 °C and 
2000 × g for 5 min. 
 
The supernatant was transferred to a new borosilicate glass tube (13 × 100 mm) and 
evaporated at 35 ◦C to dryness under a stream of Argon. The residue was dissolved in 100 µL of 
the reconstitution solution and subjected to LC-MS/MS analysis.  
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2.2.6. Mass Spectrometry  
 
Liquid chromatography-mass spectrometry (UPLC-MS) was performed on the cardiolipin 
sample and the breast cancer cell lines in order to detect cardiolipin and the standard within the 
cells. Waters Acquity UPLC system, Waters Xevo G2-S QToF MS was the instrument used to 
perform mass spectrometry analysis. 
 
Table 1: Chromatographic conditions for CL analysis: 
Time Flow % iPrOH/acetonitrile +0.05% 
FA 
% 20 mM NH4Ac + 5% MeOH, 
pH 9 
Curve 
0.00 0.3 75.0 25.0 6 
8.00 0.3 100.0 0.0 6 
12.00 0.3 100.0 0.0 6 
 
Table 2: UPLC-MS parameters for CL analysis 
MS Scan 50-1800 Da 
ESI MS Negative mode 
Capillary 2.8 kV 
Cone 12 
Source temperature 80 C 
Desolvation temperature 480 C 
Desolvation Gas Flow 1000 L/hr 
Cone Gas Flow 50 L/hr 
Collision Low Energy 20 eV 
Collision Energy Elevated 30-50 eV 
MS Lockspray Leucine-enkephalin at MS 554.2615, 
The lock mass at a concentration of 5 µg/mL and 
flow rate of 10 µL/min 
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2.2.7. Molecular Networking 
 
Cardiolipin (C14:0) and bovine heart Cl raw files were converted to the mzXML format 
using msconvert (ProteoWizard version 3.0.10141) for further processing. Then, the data were 
uploaded to Uploading data for MassIVE repository of GNPS using the default parameters 
(MassIVE Accession is MSV000083087). After Molecular Networking workflow was completed 
utilizing GNPS, analysis was done within the web interface. The GNPS web interface provides an 
easy and quick way to perform initial analysis of the data, particularly if it is required that the MS2 
spectra of the nodes/clusters/networks generated be viewed by the Molecular Networking 
workflow. Lastly, the data were downloaded into Cytoscape (3.7.0) for visualization. 
 
The molecular networking parameter which created using the online workflow at GNPS. 
The data was filtered through excluding all MS/MS peaks within ± 17 Da of the parent m/z. 
MS/MS spectra were window filtered by selecting only the top 6 peaks in the ± 50Da window 
throughout the spectrum. Then, data was clustered with MS-Cluster with a precursor mass 
tolerance of 2.0 Da and MS/MS fragment ion tolerance of 0.5 Da to form consensus spectra. 
Further, consensus spectra that contained less than two spectra were discarded. After that, the 
network was created where edges have a cosine score more than 0.7 and above six matched peaks. 
Additional edges between two nodes were kept in the network if each of the nodes come out in 
each other's respective top 10 most similar nodes. Then, the spectra in the network were searched 
against GNPS' spectral libraries. The library spectra were filtered in a similar way as the input 
data. Finally, all matches retained between network and library spectra were had to have a score 
more than 0.7 and at least six matched peaks.  
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2.2.8. Data 
 
Data comparison was performed on cell viability data with one-way ANOVA with 
concentration of compound as the fixed factor, followed by Bonferroni post hoc analyses using 
GraphPad Prism 8.2.1 version. Two independent experiments for each cell line and n =3 for each. 
Differences between data sets were considered statistically significant when p < 0.05. Because the 
two independent experiments were performed in different days, Two-way ANOVA test with 
concentration of compound and time as the fixed factors, was used to determine if there are any 
significant effects of the time as a predictor on the % of inhibition between the two experiments. 
Using R version 3.5.1, the concentration of the compound, time of the study, and their interactions 
were run. The triplicate raw data of each experiment were used in statistics after log transformation 
were done. The data was normally distributed.   
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2.3. Results  
2.3.1. Cell viability results 
 
The effects of CL remodeling alteration introduced by phospholipase inhibitors on cell 
proliferation/viability were examined in a panel of established human breast cancer cell lines. The 
Concentration-response studies of Bel and halopemide on cell proliferation were established to 
find out the concentrations that inhibit enzymatic activities, without pronounced cytotoxicity to 
use it in the following studies.  
  
Following 48 h of compound treatment, all compounds affected cell proliferation/viability 
to a certain extent. The bromoenol lactone (BEL) showed a more potent effect than halopemide in 
all cell lines. More significant inhibitory activity was observed in the TNBC MDA-MB-231-
derived bone metastatic BoM1833 (BoM) and MDA-MB-231in comparison to the ER+ 
/PR+/HER2– MCF-7 (MCF-7)-derived subclones MCF-7-BoM when the cells were treated with 
halopemide (Figure 6). 
 
The protein synthesis inhibitor cycloheximide (CHX, 10 µM) was used as a positive control 
which resulted in 69 ± 2, 70 ± 1, 60 ± 2, and 58 ± 4 % of inhibition to the control in MDA-MB-
231, BoM, MCF-7, and MCF-7/BoM cell lines, respectively. 
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Figure 6. Concentration-response results of Bel and halopemide on cell 
proliferation/viability.MDA-MB-231, BoM, MCF-7 and MCF-7-BoM cells were exposed to Bel 
and halopemide at the concentrations of 0.3, 1, 3, 10, 30 and 60 µM. After 48 h, cell viability was 
determined and presented as “% Inhibition” of the media control. Data shown are average +/- 
standard deviation. Two separate experiments, n=3 for each experiment. X axis is log 
(concentration). There was no significant effect for the time and its interaction with the 
concentration (2-way ANOVA: F1,28= 0.927, P= 0.35). Then, one-way ANOVA was run in prism 
8.2.1. with concentration of compound as the fixed factor 
 
  
Since the logarithmic axis plots the logarithms of the values, it is only possible to plot 
positive values on logarithmic axes. There is no place to put 0.0 or negative values. The control 
results are 0 ± 5, 0 ± 6, 0 ± 5, and 0 ± 3 in MCF-7/BoM, MCF-7, BoM, and MDA-MB-231 
respectively because it is not showing in the graph.  
 MCF7/BoM
MCF7
BoM
 MDA-MB231
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Table 3: IC50 values and 95% confidence interval (CI) of bromoenol lactone (BEL) in breast cancer 
cell lines 
Bromoenol 
Lactone 
MCF-7/BoM MCF-7 BoM MDA-MB-231 
IC50 (M) 2.07x10
-5 2.36x10-5 2.75x10-5 2.67x10-5  
95% CI (M) 1.12x10-5–
3.02x10-5 
1.36x10-5–
3.36x10-5 
6.78x10-6–
4.81x10-5 
1.32x10-5–
4.02x10-5 
 
 
Table 4: IC50 values and 95% confidence interval (CI) of halopemide in breast cancer cell lines 
Halopemide MCF-7/BoM MCF-7 BoM MDA-MB-231 
IC50  2.49x10
-5 2.04x10-5 2.46x10-5 9.24x10-6  
95% CI 3.53x10-6–
4.64x10-5 
3.19x10-6–
3.76x10-5 
2.27x10-6–
5.18x10-5 
3.25x10-6–
1.52x10-5 
 
  
Table 3 and Table 4 offer a vivid analysis of the two inhibitors on the cell lines. At a 
confidence interval of 95%, similar results to Figure 6 are indicated. Bromoenol lactone has 
significantly different but potent changes as opposed to halopemide. 
  
After the viability and proliferation study were performed and the IC50 values were 
established, 10 μM concentration of BEL and halopemide were chosen for the following studies 
which have enzymatic inhibitory activity with less cytotoxicity effect.  
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2.3.2. Clonogenic assay results 
 
Clonogenic assays were performed to assess the ability of phospholipase inhibitors on the 
colony-forming ability of single of BoM cell lines. Figure 7 Cells seeded at low density were 
exposed to test compounds (bromoenol lactone and halopemide each at 1, 10 μM, and 
cycloheximide 10 μM) for 24 h. The conditioned media were replaced with growth media. After a 
ten-day period, the cells were fixed and stained. The positive control CHX blocked colony 
formation. However, Bromoenol lactone and halopemide 10 μM shows significant reduction in 
the cells ability to create colony in MDA-MB-231 and BoM comparing to theirs effect on MCF-
7-BoM. Moreover, Colony suppressing activity of 1 μM concentration of both Bel and halopemide 
compared to 10 μM were less pronounced. The cells demonstrated at different levels of exposure 
highlighted how phospholipase inhibitors influence the cancer cells in colony formation. 
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 BoM MDA 231 MCF-7 MCF-7/BoM 
Control     
CHX 10 μM     
Bel 1 μM     
Halopemide  
1 μM 
    
Bel 10 μM     
Halopemide  
10 μM 
    
Figure 7. Clonogenic survival results. Cells seeded at low density were exposed to compounds 
(Bromoenol lactone, halopemide each at 1, 10 µM, and cycloheximide 10 µM) for 24 hrs. Images 
shown are crystal violet-stained colonies from media control and compound treated wells. 
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2.3.3. The Seahorse XF Cell Energy Phenotype results 
 
The Seahorse XF Cell Energy Phenotype Test is used to generate a holistic, functional view 
of the metabolic phenotype of your cells. Definitive features were drawn through the use of energy-
producing pathways, thereby creating the best cell mitochondrial respiration and glycolysis 
process. 
 
 This preliminary experiment showed the trend in to major energy producing pathways of 
the cell mitochondrial respiration and glycolysis; measures mitochondrial respiration and 
glycolysis under baseline and stressed conditions, to reveal the three key parameters of cell energy 
metabolism: Baseline Phenotype, Stressed Phenotype, and Metabolic Potential. There were two 
sets of cells. First set, cells were cultured in 10% fetal bovine serum (FBS) including control and 
treated cells with either 30 μM Bel or 10 μM halopemide. Second set, cells were cultured in 
Charcoal Stripped Fetal Bovine Serum (CS-FBS) which is stripped of its fatty acids.  
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Figure 8. Energy phenotypes of MDA-MB-231 and MCF-7 cells. Each cell line was cultured in 
media supplemented with either regular FBS or charcoal stripped CS-FBS then exposed to BEL 
at 30 µM and halopemide at 10 µM concentrations, using OCR and ECAR in baseline and stressed 
test. A) OCR in baseline and stressed test for MDA-MB-231 cells B) OCR in baseline and stressed 
test for MCF-7 cells. C) ECAR in baseline and stressed test for MDA-MB-231. C) ECAR in 
baseline and stressed test for MCF-7 cells. Regular FBS or CS-FBS  
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For the MDA-MB-231 cells Oxygen Consumption Rates, baseline is more than stressed 
compared only in control in OCR compared with that in ECAR. In other words, comparing OCR 
and ECAR, baseline is less than stressed for CS-FBS-control (C Control), 30 Bel, CS-FBS-30 
Bel (C 30 Bel), 10 halopemide, and CS-FBS-10 halopemide (C 10 halopemide). Considering 
MCF-7-oxygen consumption Rates, the baseline is less than stressed in all factors in both OCR 
and ECAR. Also, it is clear that the difference between the baseline and the stressed is the most 
significant in ECAR MCF-7-Oxygen Consumption Rates compared with that of all others. In 
comparison with MCF-7, MDA-MB-231 shows significant increase in ECAR rate in both baseline 
and stressed in both control and with the C 30 μM Bel. while there was significant reduction in 
MCF-7 cell line C10 halopemide. In MDA-231-XF Cell Energy Phenotype, there is a decrease in 
C Control, 30 Bel, C 30 Bel, 10 halopemide, and C 10 halopemide, except for Control. In MCF-
7-XF Cell Energy Phenotype, there is a more significant decrease in C Control, 30 Bel, C 30 Bel, 
10 halopemide, and C 10 halopemide as well as Control compared with those in MDA-231-XF 
Cell Energy Phenotype. Among all, 30 Bel shows the most drastic decrease in MCF-7-XF Cell 
Energy Phenotype.   
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Figure 9. Energy phenotypes graph of MDA-MB-231 and MCF-7 cells. Each c 
ell lines had cultured in supplemented media with either Regular FBS or CS-FBS, then the cells 
were exposed to Bel at 30 µM and halopemide at 10 µM concentration.  
 
 The MCF-7 celle showed the same pattern which moves from quiescent toward energetic 
phenotype but no significant results compared to the control while MDA-MB-231 cells show a 
significant movement under stressed. More importantly, the cells that had been maintained in 
media supplemented with CS-FBS showing dramatic reduction in energy phenotype compared 
with cells that had been cultured in media with regular FBS. 
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2.3.4. CL extraction results 
 
The MS results generated from breast cancer cell lines CL extraction, using 60x106 cells 
of MCF-7/BoM, and 20x106 cells of MCF-7, BoM and MDA-231, did display the peak for the 
cardiolipin internal standard with relative high recovery from MCF-7/BoM in compare to the rest 
of the cell lines (Figure 10). The same result presented in in Figure 11 showing the chromatogram 
of IS extracted from the cells. More importantly, three different species of cardiolipin were 
extracted from MCF-7/BoM and MDA-231 cells.  
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Figure 10. Abundance/intensity of CL Internal standard (C14:0), which has 1239.8862 m/z [M-
H]-, and the extracted CL, from BoM, MCF-7, MCF-7-BoM, and MDA-MB-231 cell lines, 
(C18:2) which has 1447.9051 m/z. 
 
 
Figure 11: Chromatogram of the internal standard CL alone and the extracted IS from MCF-
7/BoM, MCF-7, BoM, and MDA-231. 
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Figure 12. Mass spectrum of the molecular CL (72:5) and (70:5) or CL (70:20) which had 
1454.0134 and 1425.9695 m/z, respectively. 
 
The extracted CL annotation was based on manual dereplication by comparing the 
predicted molecular formulae against multiple public or commercially available databases. The 
tetralinoleoylcardiolipin, 1447.9 m/z, had been extracted with very low abundance. In addition to 
a relative higher abundance CL (72:5) and (70:5) which had 1454.0134 and 1425.9695 m/z, 
respectively (Figure 12). Table 5 shows the fatty acid composition of each CL molecular species. 
These results confirm what was discussed above that the breast cancer cells shift the cardiolipin 
remodeling toward having less unsaturated species of CL.  
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Table 5: The possible fatty acid composition for each molecular species and the mass spectra in 
[M-H]- 
Molecular Species [M-H]- m/z Possible fatty acid 
composition 
CL(72:8) 1447.9  (C18:2)4 
(C16:1)1/(C18:1)1/(C18:2)1/(C20:4)1 
CL(70:5)  1425.9 (C16:0)1/(C18:1)1/(C18:2)2 
(C16:1)1/(C18:1)2/(C18:2)1 
CL(72:5) 1454.01 (C18:1)3/(C18:2)1 
 
 
 
2.3.5. Molecular Networking of the standards 
 
The MS/MS (MS2 ) data that generated from UPLC-MS of CL standards were uploaded to 
the publicly accessible Global Natural Product Social Molecular Networking (GNPS) platform 
(http://gnps.ucsd.edu), which was analyzed according to the molecular networking (MN) online 
workflow.43 To visualize the resulting networks, Software Cytoscape (Version 3.7.0) was used.  
 
According to Olivon F. group, the MS Cluster cannot differentiate between the 
chromatograph of well-resolved isomers as retention times are not considered. Annotation with 
predicted chemical formulas is also semi quantification and not implemented is only based on the 
number of MS2 scans.44 In spite of valuable outputs, some improvements are still required to 
generate unambiguous GNPS molecular networks. The MS Cluster algorithm implemented on the 
Global Natural Product Social Molecular Networking platform was developed for the 
identification of redundant spectra from the same molecule and their replacement with a single 
averaged spectrum.44 Based on the premise that the occurrence of truly the molecular eluting at 
different retention times (RTs) in liquid chromatography (LC) is rather uncommon, MS-Cluster 
developers did not integrate RT information for restricted clustering over limited RT ranges. 
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Moreover, the GNPS quantification system simply depends on the number of MS2 spectra 
detected for each precursor ion. This method is highly dependent on the data-dependent acquisition 
mode parameters, such as the number of precursor ions per scan, ion intensity threshold, and 
exclusion rules. For that, GNPS quantification only leads to a rough approximation of relative or 
absolute abundances.44 Subsequently, the parent ions at m/z 1239.8, 1447.9, and 1449.9 (Figure 
13), showed that isomers eluted at different RT were well separated in different nodes having the 
same parent ions. Cardiolipin’s (14:0)4 RT are 3.94, 3.36, 3.22, and 3.18 min. The bovine heart 
cardiolipin’s (18:2)4 RT are 3.89, 3.63 min while (18:2)3/ (18:1)1 CL’s RT are 4.15, and 3.7 min. 
In Table 6 the fatty acid composition of each standard cardiolipin were displayed.  
43 
 
 
 
 
 
Figure 13. Molecular cluster observed from CL standards. Numbers within the nodes indicate 
parent ions. Edge thickness represents the cosine similarity between nodes as well as the chemical 
structures of each compound (MassIVE Accession is MSV000083087) 
 
 
Table 6: Cardiolipin standards fatty acyl chain composition and the mass [M-H]- of each 
cardiolipin species 
 
Fatty acid composition m/z 
Bovine heart CL  (C18:2)4 1447.9 
 
(C18:2)3/(C18:1)1 1449.9 
Synthetic CL (IS)  (C14:0)4 1239.8 
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2.4. Discussion  
This proposed research focuses on the mitochondrial membrane phospholipid CL. Changes 
in CL abundance and composition can lead to mitochondrial dysfunction, metabolic abnormalities, 
and altered apoptotic response. Our objective is to identify the CL profiles associated with 
treatment response and to enhance drug sensitivity in metastatic breast cancer cells by altering CL 
side chain length/unsaturation. To alter CL composition by suppressing CL remodeling, breast 
cancer cell lines were exposed to two differentially targeted phospholipase inhibitors. First, to set 
up a method for detecting changes in cardiolipin composition within the cell lines. Liquid 
chromatography-mass spectrometry (LC-MS) was performed on each cell line cardiolipin extracts 
and cardiolipin standards. The main target of GNPS is to be an open-access knowledge base for 
community-wide organization as well as sharing of raw, identified or processed tandem mass 
(MS/MS) spectrometry data. It assists in discovery and identification throughout the entire life 
cycle of data; starting from initial data acquisition/analysis to post publication. For that, GNPS is 
considered a data-driven platform for the storage, analysis, and.43 knowledge dissemination of 
MS/MS spectra that allows community sharing of raw spectra, continuous annotation of deposited 
data, and collaborative curation of reference spectra. Currently, GNPS is the only public 
infrastructure that allows molecular networking. The molecular networks (MN) visualization in 
GNPS represents each spectrum as a node, and spectrum-to-spectrum alignments as connections 
(edges) between nodes. Nodes can be supplemented with metadata, including dereplication 
matches or knowledge that is provided by the user, for instance origin of product, abundance, 
hydrophobicity or biochemical activity, which can be reflected in the color or size of a node. To 
visualize the map of related molecules by either a molecular network online at GNPS or exported 
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for analysis in Cytoscape.43 However, as one of the drawback of MN the GNPS quantification 
system simply depends on the number of MS2 spectra detected for each precursor ion. Moreover, 
MS-Cluster developers did not integrate RT information for restricted clustering over limited RT 
ranges.44 
 
Noticeably, the MS-Cluster shows as parent ions of the CL standards at m/z 1239.8, 1447.9, 
and 1449.9 (Figure 13), indicated well separated nodes share the same parent ions and connected 
with edge represents the similarity, 0.99 cosine in 1239.8 MN, and in the bovine heart molecular 
net working the highest cosine score is 0.91 where the lowest one is 0.83. The isomers eluted at 
different RT is displayed as distinct node carried the same parent ion number. Preprocess the data 
before MN analysis might be an option to improve the analysis workflow in order to keep the MS-
Cluster option disabled.  
 
The phospholipase inhibitors used in the research combined two sets of data that required 
One-way ANOVA to analyze. The experiments used a cell line and n=3 to assess the different 
inhibitors and their effects on the compounds. A combination of CHX, bromoenol lactone (BEL), 
and halopemide in determining the cell lines was significant in the process. The main aim of the 
research is to measure the best inhibitor that can be used in remodeling the alteration on cell 
proliferation or viability while being examined for human breast cancer cell lines. The cell lines 
were significantly measured for the measured inhibitory activity that was premised in the research 
outcomes. Breast cancer cell lines used in the research were TNBC MDA-MB-231-derived bone 
metastatic BoM1833 (BoM) and MDA-MB-231in comparison to the ER+ /PR+/HER2– MCF-7 
(MCF-7)-derived subclones MCF-7-BoM. Each was analyzed differently with the reagents to 
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highlight differences that could be drawn from the specific inhibitors. Results showed that the 
bromoenol lactone inhibitor had a more potent effect than halopemide in all the cell lines. In 
examining the potential for cancer, specific inhibitors used are potent for making the right 
decisions and developing perfect methods to align with the set hypothesis being tested. Although 
halopemide and bromoenol lactone were effective methods, the overall potent changes were 
observable on BEL. Halopemide is believed to be an effective inhibitor in most of the tests. 
However, from the research, BEL has more potent changes that are pertinent in defining the 
contextual measures needed. Figure 6 presents differences in the cell lines with the two inhibitors. 
TNBC MDA-MB-231-derived bone metastatic BoM1833 (BoM) and MDA-MB-231in 
comparison to the ER+ /PR+/HER2– MCF-7 (MCF-7)-derived subclones MCF-7-BoM were used 
to accentuate the specific patterns necessary in confounding the changes. The research highlights 
variability invisibility among the cell lines when exposed to each inhibitor. BEL does not have 
clear indications in comparison to the halopemide table. While being exposed to concentrations of 
0.3, 1, 3, 10, 30, and 60 µM, there were differences in the contextual evidence indicated. 
 
Table 3 and Table 4 offer a vivid analysis of the two inhibitors on the cell lines. At a 
confidence interval of 95%, similar results to Figure 6 are indicated. Bromoenol lactone has 
significantly different but potent changes as opposed to halopemide. The distinctive features 
highlight the use of each method as an inhibitor in research for breast cancer. Various results and 
compounding attributes are generally developed and mapped through the patterns, and practical 
ways indicated. The data gives a vivid description and difference among the specific values listed 
in the cell lines. Tabulated data used is easy to track and contextualize in drawing proper inferences 
from the results given. The MCF-7/BoM, MCF-7, BoM, MDA-MB-231 data sets indicate critical 
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patterns that need to be analyzed when pulling on the specific inhibitors indicated. Every paradigm 
has explicitly been contextualized in the research tools mapping out accurate results significant in 
the research. Inhibition patterns are reflective of the cell lines and pertinent features processed on 
each experiment. Every experiment is specifically drawn and authenticated through mirroring the 
ultimate features indicated, thereby underlying the needs perpetuated in the system accordingly. 
In cancer research, as evident from the research collected on the two inhibitors, Bromoenol lactone 
offers the best chance of measuring the cancer lines. Changes and any potent attribute that 
characterizes the individual features can be easily analyzed and drawn from the research tools, and 
context indicated accordingly. In research, the specific features are essential in mapping out all the 
patterns from the data collected. Values for every element and the overall tools created to highlight 
the need to develop specific intervals and methods necessary in building a sturdy construct 
essential for change accordingly.   
 
Clonogenic assay results were also used in assessing the ability of phospholipase inhibitors 
on the colony-forming ability of single BoM cell lines. The process used different methods of 
analysis and drawing on the CHX inhibitor in comparison to the BEL and halopemide inhibitors.45 
Using positive control through the CHX inhibitors, data on individual patterns were used to assess 
CHX colony formation. The specific data sets were drawn with a particular contextual model being 
used in addressed different features as individually pronounced. Each element was critically 
integrated, thereby modeling the main methods and analysis of effective measures needed 
accordingly. The conditions were perfect in understanding different concentrates and drawing on 
specific patterns that were categorized in the research process. Results indicated that positive 
control CHX blocked colony formation. On the flip side, however, BEL and halopemide showed 
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a significant reduction in cells' ability to create a colony on the cell lines used. The cells 
demonstrated at different levels of exposure highlighted how inhibitors influence the cancer cells 
in colony formation.  Figure 2 Cells seeded at low density were exposed to compounds (Bromoenol 
lactone, halopemide each at 1, 10 µM, and cycloheximide 10 µM) for 24 hrs highlighted the 
significant differences that can be drawn.46 At each level, the results were remarkable, especially 
with positive control of the inhibitors. The three inhibitors used in the research were critical in 
outlining differences in cell formation for cancer cell lines with different concentrations. It is 
imperative to note that increasing the frequency from 1 µM to 10 µM, in halopemide and BEL led 
to an increase in the level of colony formation. Different dynamics were potent in actualizing the 
main measures and identifying appropriate tools necessary in acting as blockers in the experiment. 
Understanding the dynamics indicated helped in achieving the processes and defining critical 
features that were necessary for developing specific methods and controls needed in the systems 
accordingly. Every construct was informed on the measures and techniques used by the research 
to draw on the inhibitors and actualize the systems created. Definitive features were necessarily 
highlighting the need to address the questions raised through the use of two inhibitors in the 
experiment. 
 
Seahorse XF Energy Phenotype results were used as a functional test to generate a holistic, 
practical view of the metabolic phenotype of the cells. Definitive features were drawn through the 
use of energy-producing pathways, thereby creating the best cell mitochondrial respiration and 
glycolysis process. Understanding the glycolysis processes through the baseline and stressed 
conditions helped in addressing different parameters used in the process.48 Baseline phenotype 
highlighted phenotype and metabolic potential were the main models used in treating the cells and 
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effective measures used. Different sets of trials were conducted in a controlled environment to 
analyze the role of inhibitors in the process. 
 
In comparing OCR and EACR in the test results indicates significant changes and positions 
that are critical in underpinning the main trends in the process. While analyzing the two under the 
baseline levels, the baseline is less than stressed in all factors. Using the cell lines to assess the 
different inhibitors and control processes help in actualizing the main features and accentuating 
the patterns indicated accordingly. Significant changes and models that can be drawn from the 
OCR and EACR help in further establishing a conclusion on halopemide and BEL. The control 
rates indicate the differences in stress levels for BEL and halopemide. The significant difference 
is drawn with ten halopemide showing a reduction in stress for the MCF-7 cell line. The dynamics 
are similar in C-control, however, for the cells in the process for halopemide as well as BEL. 
Individual factors are drawn from the premise indicated mapping out contextual basis and controls 
necessary in underlining a drastic decrease in the MCF-7-XF cell energy phenotype. 
Distinguishing features are drawn through close examination of the factors and drawing on 
underlying effective measures needed in the processes indicated. Reduction in energy phenotype 
is reminiscent of changes that were significant on the individual processes mapped accordingly. 
Every dynamic is potent and actualized through the means that have been significantly indicated 
in the procedures defined. Underlining different methods and integrating better patterns help in 
outlining differences in the processes and controls meant accordingly. Every aspect has been 
controlled through culturing of the supplemented media and helps in continually developing the 
best patterns essential in the research. In collecting data for breast cancer, a split has existed, 
especially in defining the role of inhibitors in the OCR model. The study helps in underscoring the 
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differences and actualizing specific features necessary in the processes accordingly. Objective 
analysis and examination of data help in outlining significant features that are essential in modeling 
specific patterns needed. The overall method is informed on the premise that each dynamic can be 
significantly contextualized and data collected through the measures indicated in the process.  
 
The cardiolipin extraction method also helped in underlining and defining all the main 
techniques used in the research, and identifying different parts essential in the process helped in 
creating a map that can be traced and used to collect information on the process defined in the 
long-run. The phospholipase inhibitors used in the process have been appropriately modeled to 
help in drawing the perfect results and data. The information collected highlights different parts 
that need to be characterized and contextualized when examining the role of inhibitors in breast 
cancer research and treatment plans. Functional approaches have been significantly developed in 
the research outlining pertinent features and content necessary in making the best decisions 
essential in the research process. 
 
Phospholipase inhibitors that have been used in the treatment of different conditions are 
characterized in the process. Evidence from the research highlights the primary constructs 
necessary in defining the main features and changes specified in the treatment process.47 Through 
assessing the reaction of different breast cancer cell lines, individual treatment options can be 
modeled from the research collected - every dynamic point to functional sets that are essential in 
outlining a positive method required. Halopemide and BEL inhibitors give an excellent control 
model inherent in marking specific changes in the treatment process.45 Mapping different patterns 
and changes in cell lines help in actualizing significant measures needed. Every process 
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characterizes the changes that are evident from mapping out every method and inculcating certain 
standards required. The two inhibitors have a considerable influence on the patterns and controls 
indicated accordingly. Halopemide and BEL are inhibitors that have been documented for their 
effects on cancer cell lines. Individual measures are necessary for defining the contextual 
approaches essential for fixing the cells. Metastatic cells were used in the research to assess the 
effect of inhibition in the processes indicated. Setting the cells was difficult, underscoring the need 
for research on every paradigm indicated.45 The use of different cell lines that lead to breast cancer 
was essential and effectively matched the main contextual processes indicated. Actualizing the 
specific systems and patterns helped in creating healthy controls and procedures that were 
necessary for cultivating positive outcomes in the research process accordingly. Incubating the 
cells to different degrees of temperature helped in addressing various measures that were necessary 
for the procedure. The overall method was properly correlated to derive the right results for the 
research. Research tools that were used underpinned the need to actualize and develop the specific 
measures needed in the study. An analysis of halopemide and BEL impact on cardiolipin 
modification was critical in defining the contextual methods required in the study. Identifying and 
mapping the role of inhibitors in the processes helped in outlining different changes and mapping 
out the specific patterns needed. Analysis through ANOVA helped in creating a proper control 
process for different control groups used in assessing the impact of the inhibitors on cardiolipin 
remodeling. Each inhibitor had a series of various tests that were used to examine different parts 
as essential in underlining the role of every element indicated accordingly. 
 
Further research is necessary on the CL remodeling alteration by the two inhibitors to 
increase the level of efficiency and draw on specific parts that can be used in cancer treatment. 
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More still needs to be done in addressing the cancer problem, but inhibition cardiolipin remodeling 
by phospholipase inhibitors of cancer cells provides a platform that can be used in fighting the 
condition. Drawing on the research, different parts have been defined to outline the main measures 
needed in the long-run accordingly.    
53 
 
 
APPENDIX: 
3.1. Glossary 
Oxygen Consumption Rate (OCR): The rate of oxygen concentration decreases in the assay 
medium. The OCR is a measure of the mitochondrial respiration rate of cells. Extracellular 
Acidification Rate (ECAR): The rate proton concentration (or decrease in pH) increase in the 
assay medium. ECAR is a measure of the glycolysis rate of the cells. Baseline phenotype: OCR 
and ECAR of cells at starting assay conditions (specifically, in the presence of non-limiting 
quantity of substrates). Stressed phenotype: OCR and ECAR of cells under an induced energy 
demand (specifically, in the presence of stressor compounds). Metabolic potential: Percentage 
increase of stressed OCR over baseline OCR, and stressed ECAR over baseline ECAR. Metabolic 
Potential is the measure of cells' ability to meet an energy demand via respiration and glycolysis. 
Oligomycin inhibits ATP production by mitochondria and causes a compensatory increase in the 
rate of glycolysis as the cells attempt to meet their energy demands via the glycolytic pathway. 
FCCP depolarizes the mitochondrial membrane, and drives oxygen consumption rates higher as 
the mitochondria attempt to restore the mitochondrial membrane potential. 
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